ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO353

Trial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in Hemodialysis Patients (REMOVAL-HD): A Safety and Efficacy Study

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Krishnasamy, Rathika, Australasian Kidney Trials Network, The University of Queensland, Brisbane, Queensland, Australia
  • Hutchison, Colin A., Australasian Kidney Trials Network, The University of Queensland, Brisbane, Australia

Group or Team Name

  • on behalf of the REMOVAL-HD investigators
Background

A medium cut-off (MCO) dialyzer is a novel form of hemodialysis (HD) therapy designed to increase clearances of larger middle molecules and uremic toxins but may result in short-term loss of albumin. The safety and efficacy profile following sustained use of this dialyzer has not been established.

Methods

REMOVAL-HD is an investigator led, single-arm, multi-center device study that examined the safety, efficacy and patient-centered outcomes of MCO dialyzer use in chronic HD patients over 6 months. The primary outcome was change in serum albumin between baseline and 6 months. Secondary outcomes included 4-weekly trends in serum albumin, six-minute walk test (6MWT), malnutrition inflammation score (MIS) and symptom burden using restless leg syndrome rating scale and Edmonton Symptom Assessment System Revised (ESAS-R) measured at baseline, 3 and 6 months.

Results

Of 92 enrolled participants, 87 completed the required protocol and were included for analysis. Participants had a mean age of 67± 15 years, 63% were men and 51% were diabetic. The average serum albumin decreased by 1.06 g/L (95% confidence interval [CI] 0.43,1.69], or 2.92%, from baseline. The trend in serum albumin during the intervention period is shown in Figure 1. A sustained, unexplained reduction in serum albumin (>25%) was not observed in any participant. Functional and nutritional assessment using 6MWT (Δ5.7m 95% CI -29.9, 41.3) and MIS (Δ-0.4 95%CI -0.9, 0.1) were stable throughout the treatment period. Similarly, there was no significant change in patient-reported symptom burden.

Conclusion

Regular HD using the MCO dialyzer in a chronic HD population resulted in a small but acceptable reduction in serum albumin. Future randomised controlled trials should now assess the impact of the MCO dialyzer on clinical and long-term patient-centered outcomes.

Trend in serum albumin under MCO dialyzer use

Funding

  • Commercial Support